Literature DB >> 18472234

Ocular pharmacokinetics of acyclovir amino acid ester prodrugs in the anterior chamber: evaluation of their utility in treating ocular HSV infections.

Suresh Katragadda1, Sriram Gunda, Sudharshan Hariharan, Ashim K Mitra.   

Abstract

PURPOSE: To evaluate in vivo corneal absorption of the amino acid prodrugs of acyclovir (ACV) using a topical well model and microdialysis in rabbits.
METHODS: Stability of L-alanine-ACV (AACV), L-serine-ACV (SACV), L-isoleucine-ACV (IACV), gamma-glutamate-ACV (EACV) and L-valine-ACV (VACV) prodrugs was evaluated in various ocular tissues. Dose-dependent toxicity of these prodrugs was also examined in rabbit primary corneal epithelial cell culture (rPCEC) using 96-well based cell proliferation assay. In vivo ocular bioavailability of these compounds was also evaluated with a combination of topical well infusion and aqueous humor microdialysis techniques.
RESULTS: Among the amino acid ester prodrugs, SACV was most stable in aqueous humor. Enzymatic degradation of EACV was the least compared to all other prodrugs. Cellular toxicity of all the prodrugs was significantly less compared to trifluorothymidine (TFT) at 5mM. Absorption rate constants of all the compounds were found to be lower than the elimination rate constants. All the prodrugs showed similar terminal elimination rate constants (lambda(z)). SACV and VACV exhibited approximately two-fold increase in area under the curve (AUC) relative to ACV (p<0.05). Clast (concentration at the last time point) of SACV was observed to be 8+/-2.6microM in aqueous humor which is two and three times higher than VACV and ACV, respectively.
CONCLUSIONS: Amino acid ester prodrugs of ACV were absorbed through the cornea at varying rates (ka) thereby leading to varying extents (AUC). The amino acid ester prodrug, SACV owing to its enhanced stability, comparable AUC and high concentration at last time point (Clast) seems to be a promising candidate for the treatment of ocular HSV infections.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18472234      PMCID: PMC2528302          DOI: 10.1016/j.ijpharm.2008.03.015

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  37 in total

Review 1.  Prodrugs. Do they have advantages in clinical practice?

Authors:  V J Stella; W N Charman; V H Naringrekar
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

2.  Topical carbonic anhydrase inhibitors IV: Relationship between excised corneal permeability and pharmacokinetic factors.

Authors:  M G Eller; R D Schoenwald; J A Dixson; T Segarra; C F Barfknecht
Journal:  J Pharm Sci       Date:  1985-05       Impact factor: 3.534

3.  Identification and characterization of a Na+-dependent neutral amino acid transporter, ASCT1, in rabbit corneal epithelial cell culture and rabbit cornea.

Authors:  Suresh Katragadda; Ravi Sankar Talluri; Dhananjay Pal; Ashim K Mitra
Journal:  Curr Eye Res       Date:  2005-11       Impact factor: 2.424

4.  The rate of aqueous humor formation in buphthalmic rabbit eyes.

Authors:  P R McMaster; F J Macri
Journal:  Invest Ophthalmol       Date:  1967-02

5.  Effect of mono- and di-acylation on the ocular disposition of ganciclovir: physicochemical properties, ocular bioreversion, and antiviral activity of short chain ester prodrugs.

Authors:  Clapton S Dias; Banmeet S Anand; Ashim K Mitra
Journal:  J Pharm Sci       Date:  2002-03       Impact factor: 3.534

6.  Amino acid prodrugs of acyclovir as possible antiviral agents against ocular HSV-1 infections: interactions with the neutral and cationic amino acid transporter on the corneal epithelium.

Authors:  Banmeet S Anand; Suresh Katragadda; Yasser E Nashed; Ashim K Mitra
Journal:  Curr Eye Res       Date:  2004 Aug-Sep       Impact factor: 2.424

7.  Mechanistic and quantitative evaluation of precorneal pilocarpine disposition in albino rabbits.

Authors:  V H Lee; J R Robinson
Journal:  J Pharm Sci       Date:  1979-06       Impact factor: 3.534

Review 8.  Acyclovir. A review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  D M Richards; A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-11       Impact factor: 9.546

Review 9.  Acyclovir: discovery, mechanism of action, and selectivity.

Authors:  G B Elion
Journal:  J Med Virol       Date:  1993       Impact factor: 2.327

10.  Small Neutral Amino Acid Ester Prodrugs of Acyclovir Targeting Amino Acid Transporters on the Cornea: Possible Antiviral Agents Against Ocular HSV-1 Infections.

Authors:  Katragadda Suresh; Zhu Xiadong; Talluri S Ravi; Ashim K Mitra
Journal:  Ophthalmol Eye Dis       Date:  2010-07-29
View more
  15 in total

Review 1.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

Review 2.  Novel strategies for anterior segment ocular drug delivery.

Authors:  Kishore Cholkar; Sulabh P Patel; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2012-12-05       Impact factor: 2.671

Review 3.  Ocular cytochrome P450s and transporters: roles in disease and endobiotic and xenobiotic disposition.

Authors:  Mariko Nakano; Catherine M Lockhart; Edward J Kelly; Allan E Rettie
Journal:  Drug Metab Rev       Date:  2014-05-26       Impact factor: 4.518

Review 4.  Ocular surgery after herpes simplex and herpes zoster keratitis.

Authors:  Piotr Kanclerz; Jorge L Alio
Journal:  Int Ophthalmol       Date:  2020-09-10       Impact factor: 2.031

5.  Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability.

Authors:  Shun Han; Jin-qiu Shen; Yong Gan; Hai-ming Geng; Xin-xin Zhang; Chun-liu Zhu; Li Gan
Journal:  Acta Pharmacol Sin       Date:  2010-08       Impact factor: 6.150

Review 6.  A comprehensive insight on ocular pharmacokinetics.

Authors:  Vibhuti Agrahari; Abhirup Mandal; Vivek Agrahari; Hoang M Trinh; Mary Joseph; Animikh Ray; Hicheme Hadji; Ranjana Mitra; Dhananjay Pal; Ashim K Mitra
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

7.  Predicting chemical ocular toxicity using a combinatorial QSAR approach.

Authors:  Renee Solimeo; Jun Zhang; Marlene Kim; Alexander Sedykh; Hao Zhu
Journal:  Chem Res Toxicol       Date:  2012-11-19       Impact factor: 3.739

8.  Ocular sustained release nanoparticles containing stereoisomeric dipeptide prodrugs of acyclovir.

Authors:  Jwala Jwala; Sai H S Boddu; Sujay Shah; Suman Sirimulla; Dhananjay Pal; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2011-04       Impact factor: 2.671

9.  Transporter-targeted lipid prodrugs of cyclic cidofovir: a potential approach for the treatment of cytomegalovirus retinitis.

Authors:  Mitan R Gokulgandhi; Megha Barot; Mahuya Bagui; Dhananjay Pal; Ashim K Mitra
Journal:  J Pharm Sci       Date:  2012-04-12       Impact factor: 3.534

10.  Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids.

Authors:  Sudharshan Hariharan; Sriram Gunda; Gyan P Mishra; Dhananjay Pal; Ashim K Mitra
Journal:  Pharm Res       Date:  2008-10-29       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.